Odee: William Ramirez
OfbọChị Okike: 16 Septemba 2021
DatebọChị Mmelite: 21 Juunu 2024
Anonim
Cannabidiol (CBD) and Health | Pharmacology
Vidio: Cannabidiol (CBD) and Health | Pharmacology

Ndinaya

Cannabidiol bụ kemịkalụ na Cannabis sativa osisi, makwaara dị ka wii wii ma ọ bụ hemp. Achọpụtala ihe karịrị kemịkal iri asatọ, nke a maara dị ka cannabinoids na Cannabis sativa plant. Ọ bụ ezie na delta-9-tetrahydrocannabinol (THC) bụ isi ihe na-arụsi ọrụ ike na wii wii, a na-enwetakwa cannabidiol site na hemp, nke nwere nanị obere THC.

Igha uzo nke Ugbo Ugbo 2018 mere ka iwu kwadoro ire hemp na ngwaahịa hemp na U.S. Ma nke ahụ apụtaghị na ngwaahịa niile cannabidiol sitere na hemp bụ iwu. Ebe ọ bụ na a mụọla cannabidiol dị ka ọgwụ ọhụrụ, enweghị ike itinye ya na iwu ma ọ bụ nri nri. Ọzọkwa, cannabidiol enweghị ike ịgụnye na ngwaahịa ahịa na nkwupụta ọgwụgwọ. Cannabidiol nwere ike tinye ya na ngwaahịa "ịchọ mma" yana naanị ma ọ bụrụ na o nwere ihe na-erughị 0.3% THC. Ma, a ka nwere ngwaahịa ndị akpọrọ dị ka ihe mgbakwunye nri n'ahịa nwere cannabidiol. Ọnụ ọgụgụ nke cannabidiol dị na ngwaahịa ndị a anaghị ekwukarị nke ọma na akara ngwaahịa ahụ.

A na-ejikarị Cannabidiol eme ihe maka ọgba aghara (epilepsy). A na-ejikwa ya maka nchekasị, mgbu, ọrịa akwara a na-akpọ dystonia, ọrịa Parkinson, ọrịa Crohn, na ọtụtụ ọnọdụ ndị ọzọ, mana enweghị ezigbo ihe mmụta sayensị iji kwado ojiji ndị a.

Natural Medicines Comprehensive database ọnụego na-arụ ọrụ dabere na ihe akaebe sayensị dịka usoro a si dị: Mmetụta, Ikekwe Ọ Ga-arụpụta Ihe, Ikekwe Ọ Ga-arụpụta Ihe, Ikekwe Ọ Dị Irè, Ikekwe Ọ Dị Irè, Adịghị Eme Ihe, na Ego ezughi ezu iji gosi.

Radị irè maka AKWIKWỌ (CBD) ndị dị ka ndị a:


Ikekwe ọ dị irè maka ...

  • Ọrịa ọdịdọ (akwụkwụ). E gosipụtara otu ngwaahịa cannabidiol (Epidiolex, GW Pharmaceuticals) iji belata njide na ndị okenye na ụmụaka nwere ọnọdụ dịgasị iche iche metụtara njikọta. Ngwaahịa a bụ ọgwụ ọgwụ edere maka ịgwọ njide nke Dravet syndrome, ọrịa Lennox-Gastaut, ma ọ bụ mgbagwoju tubular sclerosis. E gosipụtakwala iji belata njigide na ndị nwere ọrịa Sturge-Weber, ọrịa ọrịa na-efe efe metụtara ọrịa febrile (FIRES), na ọrịa mkpụrụ ndụ ihe nketa kpọmkwem nke na-akpata encephalopathy. Mana anabataghị ya maka ịgwọ ụdị ọgụ ndị a. A na-ewere ngwaahịa a yana ọgwụ mgbochi ọgụ. Cannabfọdụ ngwaahịa cannabidiol nke emere na ụlọ nyocha na-amụkwa maka akwụkwụ. Ma nyocha dị oke, ọ nweghịkwa ngwaahịa ndị a kwadoro dị ka ọgwụ ọgwụ.

Ezughi oke akaebe iji gosipụta irè maka ...

  • Typedị ọrịa obi na-efe efe (ọrịa Crohn). Nnyocha mbụ emere na-egosi na ị cannabụ cannabidiol adịghị ebelata ọrụ ọrịa na ndị okenye nwere ọrịa Crohn.
  • Ọrịa shuga. Nnyocha emere na mbụ gosiri na ị cannabụ cannabidiol anaghị eme ka shuga shuga na-achịkwa ndị okenye nwere ụdị ọrịa shuga abụọ.
  • Nsogbu mmegharị nke akara mkpịsị akwara na-enweghị isi (dystonia). O doro anya ma ọ bụrụ na cannabidiol bara uru maka dystonia.
  • Ọnọdụ eketa eketa site na nkwarụ mmụta (ọrịa na-emebi emebi- X). Nnyocha mbụ mere na-egosi na itinye gelidio cannabidiol nwere ike belata nchekasị ma melite omume na ụmụaka nwere ọrịa X na-emebi emebi.
  • Ọnọdụ nke transplant na-awakpo ahụ (ọrịa aka-versus-host ma ọ bụ GVHD). Ọrịa graft-vesos bụ nsogbu nke nwere ike ịdapụta mgbe ọkpụkpụ ọkpụkpụ gachara. Nnyocha emere na mbụ achọpụtala na ị cannabụ cannabidiol kwa ụbọchị na-amalite ụbọchị 7 tupu ụmị ọkpụkpụ na-aga n'ihu ruo ụbọchị 30 mgbe transplant gasịrị nwere ike ịgbatị oge ọ ga-ewe mmadụ iji zụlite GVHD.
  • Ọrịa ụbụrụ anyị ketara eketa nke na-emetụta mmegharị, mmetụta uche, na iche echiche (ọrịa Huntington). Nnyocha mbụ mere na-egosi na ị cannabụ cannabidiol kwa ụbọchị adịghị eme ka ihe mgbaàmà nke ọrịa Huntington ka mma.
  • Ọrịa multiple sclerosis (MS). Nnyocha mbụ na-egosi na iji ọgwụ cannabidiol gbaa n'okpuru ire nwere ike imeziwanye ihe mgbu na akwara muscle na ndị nwere MS.
  • Nwepu na heroin, morphine, na ọgwụ ndị ọzọ opioid. Nnyocha mbụ mere na-egosi na ị cannabụ cannabidiol maka ụbọchị 3 nwere ike belata agụụ na nchekasị nke ndị nwere nsogbu ị heroụ ọgwụ heroin.
  • Ọrịa Parkinson. Nnyocha e mere na mbụ gosiri na cannabidiol nwere ike belata nchekasị na mgbaàmà mgbaàmà uche na ndị nwere ọrịa Parkinson.
  • Ọrịa. Nnyocha mbụ mere na-egosi na ị cannabụ cannabidiol na-eme ka mgbaàmà na ahụike dị mma na ndị nwere isi ihe.
  • Kwụsị ise siga. Nnyocha mbụ emere na-egosi na ịmịnye cannabidiol na inhaler maka otu izu nwere ike belata ọnụ ọgụgụ sịga nke ndị na-ese anwụrụ ọkụ na-anwa ịkwụsị.
  • Anxietydị nchekasị nke ụjọ na-atụ n'ụfọdụ ọnọdụ mmekọrịta mmadụ na ibe ya (ọgba aghara nchekasị). Nchoputa mbu gosiputara na cannabidiol nwere ike ime ka ndi mmadu nwee nsogbu a. Mana o doro anya ma ọ bụrụ na ọ na-enyere aka belata nchekasị n'oge ikwu okwu n'ihu ọha.
  • Otu ìgwè ọnọdụ na-egbu mgbu nke na-emetụta nkwonkwo agba na akwara (nsogbu oge ma ọ bụ TMD). Nnyocha mbụ emere na-egosi na itinye mmanụ nwere cannabidiol na akpụkpọ ahụ nwere ike belata ihe mgbu ndị nwere TMD.
  • Nerve mmebi na aka na ụkwụ (peripheral neuropathy).
  • Ọrịa ụbụrụ.
  • Ehighị ụra nke ọma.
  • Ọnọdụ ndị ọzọ.
Achọrọ ihe akaebe ọzọ iji gosipụta irè nke cannabidiol maka ojiji ndị a.

Cannabidiol nwere mmetụta na ụbụrụ. Ihe kpatara nsogbu ndị a edoghị anya. Otú ọ dị, cannabidiol yiri ka ọ na-egbochi nkwụsị nke chemical na ụbụrụ nke na-emetụta ihe mgbu, ọnọdụ, na ọrụ uche. Na-egbochi nkwụsịtụ nke mmiri ọgwụ a ma na-arịwanye elu n'ọbara ya yiri ka ọ na-ebelata mgbaàmà psychotic metụtara ọnọdụ ndị dị ka ịme ihe. Cannabidiol nwekwara ike igbochi ụfọdụ mmetụta psychoactive nke delta-9-tetrahydrocannabinol (THC). Ọzọkwa, cannabidiol yiri ka ọ na-ebelata ihe mgbu na nchekasị.

Mgbe e were ya n'ọnụ: Cannabidiol bụ Enwere ike nchekwa mgbe ejiri ọnụ ya ma ọ bụ fesa ya n'okpuru ire ya. Cannabidiol dị na 300 mg kwa ụbọchị ejiriwo ọnụ na-echekwa ya ruo ọnwa isii. A na-eji ọnụ dị elu nke 1200-1500 mg kwa ụbọchị n'ọnụ n'enweghị nsogbu ruo izu 4. A na-anabata ọgwụ cannabidiol ọgwụ (Epidiolex) ka a na-eji ọnụ were ọgwụ 25 mg / kg kwa ụbọchị. Cannabidiol sprays nke etinyere n’okpuru ire ejirila na doses nke 2.5 mg ruo izu 2.

Reportedfọdụ akọ mmetụta nke cannabidiol gụnyere akọrọ ọnụ, ọbara mgbali elu, isi ọwụwa, na iro ụra. E gosipụtakwala ihe ịrịba ama nke mmerụ imeju na ụfọdụ ndị ọrịa, mana nke a adịkarịghị.

Mgbe etinyere ya na akpụkpọ: Enweghị ozi zuru ezu a pụrụ ịdabere na ya iji mara ma ọ bụrụ na cannabidiol dị mma ma ọ bụ ihe mmetụta dị na ya nwere ike ịbụ.

Akpachapụ anya na ịdọ aka na ntị:

Ime ime na ara-ara: Cannabidiol bụ EBEGH UN UNSAFE iji ma ọ bụrụ na ị dị ime ma ọ bụ na-enye nwa ara. Cannabidiol ngwaahịa nwere ike merụọ ya na ndị ọzọ Efrata nwere ike na-emerụ ka nwa ebu n'afọ ma ọ bụ nwa ọhụrụ. Nọrọ na mma n'akụkụ ma zere ojiji.

Mụaka: Ngwaahịa ọgwụ cannabidiol ọgwụ (Epidiolex) bụ Enwere ike nchekwa mgbe a na-eji ọnụ were dozie ya ruo 25 mg / kg kwa ụbọchị. Ngwaahịa a kwadoro maka ojiji maka ụfọdụ ụmụaka 1 afọ na okenye.

Ọrịa imeju: Ndị nwere ọrịa imeju nwere ike iji obere ọgwụ nke cannabidiol jiri ya tụnyere ndị ọrịa ahụike.

Ọrịa Parkinson: Somefọdụ nnyocha e mere na mbụ na-egosi na ị takingụ ọgwụ ike cannabidiol dị elu nwere ike ime ka mmegharị ahụ na ịma jijiji na-akawanye njọ na ụfọdụ ndị nwere ọrịa Parkinson.

Agafeghị oke
Kpachara anya na nchikota a.
Brivaracetam (Briviact)
Ahụ Brivaracetam gbanwere ma mebie. Cannabidiol nwere ike ibelata otu ngwa ngwa ahụ na-akụda brivaracetam. Nke a nwere ike ịbawanye ogo nke brivaracetam na ahụ.
Carbamazepine (Tegretol)
Carbamazepine gbanwere ma mebie ya. Cannabidiol nwere ike belata ngwa ngwa ahụ na-emebi carbamazepine. Nke a nwere ike ime ka carbamazepine dị elu na ahụ wee nwekwuo mmetụta ya.
Clobazam (Onfi)
Clobazam gbanwere na imeju site na imeju. Cannabidiol nwere ike belata ngwa ngwa imeju na-agbari clobazam. Nke a nwere ike ime ka mmetụta nke clobazam dịkwuo elu.
Eslicarbazepine (Aptiom)
Eslicarbazepine gbanwere ma mebie ya. Cannabidiol nwere ike belata ngwa ngwa ahụ na-agbada eslicarbazepine. Nke a nwere ike ime ka eslicarbazepine dị elu na ahụ site na obere obere.
Everolimus (Zostress)
Everolimus gbanwere ma mebie ya site na ahụ ya. Cannabidiol nwere ike belata ngwa ngwa ahụ na-agbada everolimus. Nke a nwere ike ịbawanye ogo nke everolimus n'ime ahụ.
Lithium
Highernweta ọgwụ dị elu nke cannabidiol nwere ike ịbawanye ọkwa nke lithium. Nke a nwere ike ịbawanye ohere nke nsị lithium.
Ọgwụ gbanwere umeji (Cytochrome P450 1A1 (CYP1A1) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Medicationsfọdụ ọgwụ ndị imeju gbanwere gụnyere chlorzoxazone (Lorzone) na theophylline (Theo-Dur, ndị ọzọ).
Ọgwụ gbanwere umeji (Cytochrome P450 1A2 (CYP1A2) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Medicationsfọdụ ọgwụ ndị imeju gbanwere gụnyere amitriptyline (Elavil), haloperidol (Haldol), ondansetron (Zofran), propranolol (Inderal), theophylline (Theo-Dur, ndị ọzọ), verapamil (Calan, Isoptin, ndị ọzọ), na ndị ọzọ.
Ọgwụ gbanwere umeji (Cytochrome P450 1B1 (CYP1B1) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Somefọdụ ọgwụ ndị imeju gbanwere gụnyere theophylline (Theo-Dur, ndị ọzọ), omeprazole (Prilosec, Omesec), clozapine (Clozaril, FazaClo), progesterone (Prometrium, ndị ọzọ), lansoprazole (Prevacid), flutamide (Eulexin), oxaliplatin (Eloxatin) ), erlotinib (Tarceva), na caffeine.
Ọgwụ gbanwere umeji (Cytochrome P450 2A6 (CYP2A6) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Fọdụ ọgwụ ndị imeju gbanwere gụnyere nicotine, chlormethiazole (Heminevrin), coumarin, methoxyflurane (Penthrox), halothane (Fluothane), valproic acid (Depacon), disulfiram (Antabuse), na ndị ọzọ.
Ọgwụ gbanwere umeji (Cytochrome P450 2B6 (CYP2B6) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Fọdụ ọgwụ ndị imeju gbanwere gụnyere ketamine (Ketalar), phenobarbital, orphenadrine (Norflex), secobarbital (Seconal), na dexamethasone (Decadron).
Ọgwụ gbanwere umeji (Cytochrome P450 2C19 (CYP2C19) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Fọdụ ọgwụ ndị imeju gbanwere gụnyere proton pump inhibitors gụnyere omeprazole (Prilosec), lansoprazole (Prevacid), na pantoprazole (Protonix); diazepam (Valium); carisoprodol (Soma); nelfinavir (Viracept); na ndị ọzọ.
Ọgwụ gbanwere umeji (Cytochrome P450 2C8 (CYP2C8) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.
Medicationsfọdụ ọgwụ ndị imeju gbanwere gụnyere amiodarone (Cordarone), carbamazepine (Tegretol), chloroquine (Aralen), diclofenac (Voltaren), paclitaxel (Taxol), repaglinide (Prandin) na ndị ọzọ.
Ọgwụ gbanwere umeji (Cytochrome P450 2C9 (CYP2C9) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju mebiri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Medicationsfọdụ ọgwụ ndị imeju gbanwere gụnyere ọgwụ ndị na-adịghị egbochi ọgwụ ọjọọ (NSAIDs) dị ka diclofenac (Cataflam, Voltaren), ibuprofen (Motrin), meloxicam (Mobic), piroxicam (Feldene), na celecoxib (Celebrex); amitriptyline (Elavil); warfarin (Coumadin); glipizide (Glucotrol); losartan (Cozaar); na ndị ọzọ.
Ọgwụ gbanwere umeji (Cytochrome P450 2D6 (CYP2D6) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju gbariri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Fọdụ ọgwụ ndị imeju gbanwere gụnyere amitriptyline (Elavil), codeine, desipramine (Norpramin), flecainide (Tambocor), haloperidol (Haldol), imipramine (Tofranil), metoprolol (Lopressor, Toprol XL), ondansetron (Zofran), paroxetine (Proxetil) ), risperidone (Risperdal), tramadol (Ultram), venlafaxine (Effexor), na ndị ọzọ.
Ọgwụ gbanwere umeji (Cytochrome P450 3A4 (CYP3A4) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ imeju mebiri nwere ike ịbawanye mmetụta na nsonaazụ nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Fọdụ ọgwụ ndị imeju gbanwere gụnyere alprazolam (Xanax), amlodipine (Norvasc), clarithromycin (Biaxin), cyclosporine (Sandimmune), erythromycin, lovastatin (Mevacor), ketoconazole (Nizoral), itraconazole (Sporanox), trixof) (Halcion), verapamil (Calan, Isoptin) na ọtụtụ ndị ọzọ.
Ọgwụ gbanwere umeji (Cytochrome P450 3A5 (CYP3A5) substrates)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Na tiori, iji cannabidiol tinyere ọgwụ ụfọdụ nke imeju gbariri nwere ike ịbawanye mmetụta na mmetụta nke ụfọdụ ọgwụ. Tupu i jiri cannabidiol, gwa onye na-eweta ahụike gị ma ọ bụrụ nara ọgwụ ọ bụla nke imeju gbanwere.

Medicationsfọdụ ọgwụ ndị imeju gbanwere gụnyere testosterone, progesterone (Endometrin, Prometrium), nifedipine (Adalat CC, Procardia XL), cyclosporine (Sandimmune), na ndị ọzọ.
Ọgwụ gbanwere umeji (ọgwụ ọgwụ Glucuronidated)
Thefọdụ ọgwụ na-agbanwe ma mebie site na imeju. Cannabidiol nwere ike ibelata ngwa ngwa imeju na-agbari ụfọdụ ọgwụ. Iwere cannabidiol tinyere ọgwụ ụfọdụ imeju na-agbaji nwere ike ịbawanye mmetụta na nsonaazụ nke ọgwụ ndị a.
Fọdụ n'ime ọgwụ ndị a imeju gbanwere gụnyere acetaminophen (Tylenol, ndị ọzọ) na oxazepam (Serax), haloperidol (Haldol), lamotrigine (Lamictal), morphine (MS Contin, Roxanol), zidovudine (AZT, Retrovir), na ndị ọzọ.
Ọgwụ ndị na-ebelata mmebi nke ọgwụ ndị ọzọ site na imeju (Cytochrome P450 2C19 (CYP2C19) inhibitors)
A na-agbaji Cannabidiol site na imeju. Fọdụ ọgwụ nwere ike ibelata ngwa ngwa imeju imebi cannabidiol. Iwere cannabidiol tinyere ọgwụ ndị a nwere ike ịbawanye nsonaazụ na nsonaazụ nke cannabidiol.
Medicationsfọdụ ọgwụ nwere ike ibelata mmebi cannabidiol n'ime imeju gụnyere cimetidine (Tagamet), fluvoxamine (Luvox), omeprazole (Prilosec); ticlopidine (Ticlid), topiramate (Topamax), na ndị ọzọ.
Ọgwụ ndị na-ebelata mmebi nke ọgwụ ndị ọzọ na imeju (Cytochrome P450 3A4 (CYP3A4) inhibitors)
A na-agbaji Cannabidiol site na imeju. Fọdụ ọgwụ nwere ike ibelata ngwa ngwa imeju imebi cannabidiol. Iwere cannabidiol tinyere ọgwụ ndị a nwere ike ịbawanye nsonaazụ na nsonaazụ nke cannabidiol.
Fọdụ ọgwụ nwere ike ibelata etu imeju si gbarie ngwa ngwa cannabidiol gụnyere amiodarone (Cordarone), clarithromycin (Biaxin), diltiazem (Cardizem), erythromycin (E-mycin, Erythrocin), indinavir (Crixivan), ritonavir (Norvir), saquinavir (Fortovase) , Invirase), na ọtụtụ ndị ọzọ.
Ọgwụ ndị na-eme ka mmebi nke ọgwụ ndị ọzọ dị na umeji (Cytochrome P450 3A4 (CYP3A4) inducers)
A na-agbaji Cannabidiol site na imeju. Fọdụ ọgwụ nwere ike ịbawanye ngwa ngwa imeju imeju cannabidiol. Iwere cannabidiol tinyere ọgwụ ndị a nwere ike ibelata mmetụta nke cannabidiol.
Fọdụ n’ime ọgwụ ndị a gụnyere carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), na ndị ọzọ.
Ọgwụ ndị na-eme ka mmebi nke ọgwụ ndị ọzọ site na imeju (Cytochrome P450 2C19 (CYP2C19) inducers)
A na-agbaji Cannabidiol site na imeju. Fọdụ ọgwụ nwere ike ịbawanye ngwa ngwa imeju imeju cannabidiol. Iwere cannabidiol tinyere ọgwụ ndị a nwere ike ibelata mmetụta nke cannabidiol.
Fọdụ ọgwụ ndị nwere ike ịbawanye mmebi nke cannabidiol n'ime imeju gụnyere carbamazepine (Tegretol), prednisone (Deltasone), na rifampin (Rifadin, Rimactane).
Methadone (Dolophine)
Imeju na-agbaji methadone. Cannabidiol nwere ike belata ngwa ngwa imeju na-agbada methadone. Iwere cannabidiol yana methadone nwere ike ime ka mmetụta na mmetụta nke methadone dịkwuo elu.
Okwudiri (Banzel)
Rufinamide gbanwere ma mebie ya site na ahụ. Cannabidiol nwere ike belata otu ngwa ngwa ahụ si emebi rufinamide. Nke a nwere ike ime ka rufinamide dị na ahụ dịkwuo obere site na obere obere.
Ọgwụ ịgwọ ọrịa (CNS depressants)
Cannabidiol nwere ike ime ka ụra na ụra. A na-akpọ ọgwụ ndị na-akpata ihi ụra ụra. Iwere cannabidiol yana ọgwụ na-eme ka mmadụ daa ụra nwere ike ime ka ụra buru oke ụra.

Medicationsfọdụ ọgwụ na-akụda mmụọ gụnyere benzodiazepines, pentobarbital (Nembutal), phenobarbital (Luminal), secobarbital (Seconal), thiopental (Pentothal), fentanyl (Duragesic, Sublimaze), morphine, propofol (Diprivan), na ndị ọzọ.
Sirolimus (Rapamune)
Sirolimus gbanwere ma mebie ya site na ahụ. Cannabidiol nwere ike belata ngwa ngwa ahụ na-agbada sirolimus. Nke a nwere ike ịbawanye ogo nke sirolimus n'ime ahụ.
Stiripentol (Diacomit)
Stiripentol gbanwere ma mebie ya. Cannabidiol nwere ike belata ngwa ngwa ahụ na-akụda stiripentol. Nke a nwere ike ime ka stiripentol dị elu na ahụ wee nwekwuo mmetụta ya.
Tacrolimus (Mmemme)
Tacrolimus gbanwere ma mebie ya. Cannabidiol nwere ike belata otu ngwa ngwa ahụ na-etida tacrolimus. Nke a nwere ike ime ka tacrolimus dịkwuo elu n'ime ahụ.
Topiramate ntụ ntụ (Tompamax)
Topiramate mmiri na-agbanwe ma mebie ya. Cannabidiol nwere ike belata ngwa ngwa ahụ na-akụda topiramate. Nke a nwere ike ịbawanye ogo nke Topiramate na ahụ site na obere obere.
Nyochaa
Valproic acid nwere ike ibute mmerụ imeju. Iwere cannabidiol na valproic acid nwere ike ime ka ọnya imeju nwee ike. Cannabidiol na / ma ọ bụ valproic acid nwere ike ịkwụsị, ma ọ bụ belata ọgwụ ahụ nwere ike belata.
Warfarin
Cannabidiol nwere ike ịbawanye ọkwa nke warfarin, nke nwere ike ịbawanye ohere maka ịgba ọbara. Cannabidiol na / ma ọ bụ warfarin nwere ike ịkwụsị, ma ọ bụ belata ọgwụ ahụ nwere ike belata.
Zonisamide
Zonisamide gbanwere ma mebie ahụ. Cannabidiol nwere ike belata ngwa ngwa ahụ na-akụda zonisamide. Nke a nwere ike ịbawanye ogo nke zonisamide n'ime ahụ site na obere obere.
Herbs na Mmeju na ogwuura Njirimara
Cannabidiol nwere ike ime ka ụra ma ọ bụ ụra. Iji ya na ahihia ndi ozo na ihe ndi ozo nke nwere otu ihe puru ime ka ura buru oke ura. Fọdụ n'ime mkpá akwụkwọ na ọgwụ ndị a gụnyere calamus, California poppy, catnip, hops, Jamaican dogwood, kava, L-tryptophan, melatonin, sage, SAMe, St. John's wort, sassafras, skullcap, na ndị ọzọ.
Mmanya na-egbu egbu (Ethanol)
Iwere cannabidiol na mmanya na-abawanye ole cannabidiol nke ahụ na-etinye. Nke a nwere ike ịbawanye mmetụta na nsonaazụ nke cannabidiol.
Abụba na nri nwere abụba
Iwere cannabidiol na nri nke nwere abụba ma ọ bụ ma ọ dịkarịa ala nwere ụfọdụ abụba, na-eme ka ọnụ ọgụgụ nke cannabidiol na-etinye n'ahụ. Nke a nwere ike ịbawanye mmetụta na nsonaazụ nke cannabidiol.
Mmiri ara
Iwere cannabidiol na mmiri ara ehi na-eme ka cannabidiol mụbaa nke ahụ. Nke a nwere ike ịbawanye mmetụta na nsonaazụ nke cannabidiol.
A na-amụ usoro ndị a na nyocha sayensị:

NDUL okenye

Site n'ọnụ:
  • Maka akwụkwụ: Ejirila ọgwụ cannabidiol ọgwụ (Epidiolex). Ntinye mmalite nke akwadoro maka ọrịa Lennox-Gastaut na ọrịa Dravet bụ 2.5 mg / kg ugboro abụọ kwa ụbọchị (5 mg / kg / day). Mgbe otu izu gasịrị, a pụrụ ịgbatị dose ahụ ruo 5 mg / kg ugboro abụọ kwa ụbọchị (10 mg / kg / day). Ọ bụrụ na onye ahụ azaghị ọgwụ a, ihe kachasị atụ bụ 10 mg / kg ugboro abụọ kwa ụbọchị (20 mg / kg / day). Startingkpụrụ mmalite a tụrụ aro maka mgbagwoju anya nke ọrịa sclerosis bụ 2.5 mg / kg ugboro abụọ kwa ụbọchị (5 mg / kg / day). Enwere ike ịbawanye nke a kwa izu kwa izu ma ọ bụrụ na ọ dị mkpa, ruo na nke kachasị 12.5 mg / kg ugboro abụọ kwa ụbọchị (25 mg / kg / day). Enweghị ihe akaebe sayensị siri ike na ngwaahịa cannabidiol na-edeghị ederede bara uru maka akwụkwụ.
M .AKA

Site n'ọnụ:
  • Maka akwụkwụ: Ejirila ọgwụ cannabidiol ọgwụ (Epidiolex). Ntinye mmalite nke akwadoro maka ọrịa Lennox-Gastaut na ọrịa Dravet bụ 2.5 mg / kg ugboro abụọ kwa ụbọchị (5 mg / kg / day). Mgbe otu izu gasịrị, a pụrụ ịgbatị dose ahụ ruo 5 mg / kg ugboro abụọ kwa ụbọchị (10 mg / kg / day). Ọ bụrụ na onye ahụ azaghị ọgwụ a, ihe kachasị atụ bụ 10 mg / kg ugboro abụọ kwa ụbọchị (20 mg / kg / day). Startingkpụrụ mmalite a tụrụ aro maka mgbagwoju anya nke ọrịa sclerosis bụ 2.5 mg / kg ugboro abụọ kwa ụbọchị (5 mg / kg / day). Enwere ike ịbawanye nke a kwa izu kwa izu ma ọ bụrụ na ọ dị mkpa, rue ihe dịka 12.5 mg / kg ugboro abụọ kwa ụbọchị (25 mg / kg / day). Enweghị ihe akaebe sayensị siri ike na ngwaahịa cannabidiol na-edeghị ederede bara uru maka akwụkwụ.
2 - [(1R, 6R) -3-Methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl] -5-pentylbenzene-1,3-diol, CBD.

Iji mụtakwuo banyere otú e si dee isiokwu a, biko lee Natural Medicines Comprehensive database usoro.


  1. Singh RK, Dillon B, Tatum DA, Van Poppel KC, Bonthius DJ. Mkparịta ụka ọgwụ ọjọọ n'etiti Cannabidiol na Lithium. Nwa Neurol Open. 2020; 7: 2329048X20947896. Lelee anya.
  2. Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Nyocha nke pharmacokinetic nke sịntetik cannabidiol ọnụ na-emepụta ihe na ndị ọrụ afọ ofufo ahụike. Eur J Pharm Biopharm. 2020; 154: 108-115. Lelee anya.
  3. Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M. Ọdịnaya na Mkpesa Label na Cannabidiol (CBD) -Nweta ngwaahịa enwetara site na Outlọ Ahịa Azụmaahịa na Steeti Mississippi. J Dietụ nri. Ọrịa. 2020; 17: 599-607. Lelee anya.
  4. McGuire P, Robson P, Cubala WJ, et al. Amụrụ ihe Cannabidiol (CBD) dị ka ọgwụgwọ Ọrịa na Schizophrenia: Ọrịa Na-achịkwa Ọgwụ Na-enweghị Ọgwụ. 2018; 175: 225-231. Lelee anya.
  5. Cortopassi J. Warfarin dose mgbanwe achọrọ mgbe cannabidiol mmalite na titration. Am J Ahụ ike Syst Pharm. 2020; 77: 1846-1851. Lelee anya.
  6. MAP Bloomfield, Green SF, Hindocha C, et al. Mmetụta nke nnukwu cannabidiol na ụbụrụ ụbụrụ na mmekọrịta ya na ebe nchekwa: Ihe omumu ihe omimi nke ihe omuma. J Psychopharmacol. 2020; 34: 981-989. Lelee anya.
  7. Wang GS, Bourne DWA, Klawitter J, et al. Mwepu nke Cannabidiol-Rich Cannabis Extracts na Childrenmụaka nwere Akwụkwụ na-adọ. Pharmlọ ọgwụ Pharmacokinet. 2020. Elele anya.
  8. Taylor L, Crockett J, Tayo B, Checketts D, Sommerville K. Mbibi nke cannabidiol (CBD): Ọnwụnwa enweghị usoro. Akwụkwụ na-adọ Behav. 2020; 104 (Pt A): 106938. Lelee anya.
  9. McNamara NA, Dang LT, Sturza J, et al. Thrombocytopenia na ụmụaka na-arịa ọrịa na cannabidiol na valproic acid. Akwụkwụ. 2020. Elele anya.
  10. Rianprakaisang T, Gerona R, Hendrickson RG. Azụmaahịa cannabidiol azụmahịa nke emetọ na sịntetik Cannabinoid AB-FUBINACA nyere onye ọrịa pediatric. Ọrịa Toxicol (Phila). 2020; 58: 215-216. Lelee anya.
  11. Morrison G, Crockett J, Blakey G, Sommerville K. Oge nke 1, Akwụkwọ mepere emepe, Nnyocha Pharmacokinetic iji Nyochaa Mmekọrịta ọgwụ ọjọọ na-eme n'etiti Clobazam, Stiripentol, ma ọ bụ Valproate na Cannabidiol na Ndị Ahụ Ike. Pharmlọ ọgwụ Pharmacol Drug Dev. 2019; 8: 1009-1031. Lelee anya.
  12. Miller I, Scheffer IE, Gunning B, et al. Mmetụta Na-akpata Nsogbu nke Okwu Cannabidiol Oral na nke a na-etinye na ọdụ ụgbọ mmiri na-adọkpụ na Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020; 77: 613-621. Lelee anya.
  13. Lattanzi S, Trinka E, Striano P, et al. Naịjirịa Cannabidiol nrụpụta na ọnọdụ clobazam: Nyocha nyocha na meta-analysis. Akwụkwụ. 2020; 61: 1090-1098. Lelee anya.
  14. Hobbs JM, Vazquez AR, Remijan ND, et al. Nyocha nke pharmacokinetics na nnukwu mgbochi mkpali nke nkwupụta okwu cannabidiol abụọ na okenye. Phytother Res. 2020; 34: 1696-1703. Lelee anya.
  15. Ebrahimi-Fakhari D, Agricola KD, Tudor C, Krueger D, Franz DN. Cannabidiol na-ebuli usoro ebumnuche nke Rapamycin Inhibitor Levels in Patients with Tuberous Sclerosis Complex. Pediatr Neurol. 2020; 105: 59-61. Lelee anya.
  16. de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. fficrụ ọrụ na ihe omume omume ọjọọ nke cannabidiol na ọgwụ na-agwọ ọrịa maka akwụkwụ na-eguzogide ọgwụ: Nyocha usoro na meta-analysis. Akwụkwụ na-adọ Behav. 2020; 102: 106635. Lelee anya.
  17. Darweesh RS, Khamis TN, El-Elimat T. Mmetụta nke cannabidiol na pharmacokinetics nke carbamazepine na oke. Naunyn Schmiedebergs Arch Pharmacol. 2020. Elele anya.
  18. Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G. Oge nke 1, nke a na-ahụkarị, ọgwụ pharmacokinetic nke mmetụta nke nri nri dị iche iche, mmiri ara ehi niile, na mmanya na-egosi cannabidiol na nchekwa na isiokwu ndị dị mma. Akwụkwụ. 2020; 61: 267-277. Lelee anya.
  19. Chesney E, Oliver D, Green A, et al. Ọzọ Mmetụta ọjọọ nke cannabidiol: nyocha nhazi na meta-nyocha nke ule ahụike na-enweghị usoro. Neuropsychopharmacology. 2020. Elele anya.
  20. Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. Oge nke abụọ nke usoro ikpebi iji chọpụta ihe nwere ike maka mmekọrịta ọgwụ na ọgwụ-ọgwụ na ọgwụ Stripentol ma ọ bụ Valproate mgbe ejikọtara ya na Cannabidiol na ndị ọrịa nwere Akwụkwụ na-adọ. CNS Ọgwụ. 2020; 34: 661-672. Lelee anya.
  21. Bass J, Linz DR. Okwu nke nsị site na Cannabidiol Gummy Ingestion. Cureus. 2020; 12: e7688. Lelee anya.
  22. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol na (-) Delta9-tetrahydrocannabinol bụ antioxidants neuroprotective. Nyocha Natl Acad Sci US A. 1998; 95: 8268-73. Lelee anya.
  23. Hacke ACM, Lima D, de Costa F, et al. Na-achọpụta ọrụ antioxidant nke [delta] -tetrahydrocannabinol na cannabidiol na Cannabis sativa extracts. Onye nyocha. Ọrịa. 2019; 144: 4952-4961. Lelee anya.
  24. Madden K, Tanco K, Bruera E. Mkparịta ụka ọgwụ na ọgwụ ọjọọ dị n'etiti ọgwụ Methadone na Cannabidiol. Ọrịa ụmụaka. 2020; E20193256. Lelee anya.
  25. Hazekamp A. Nsogbu dị na mmanụ CBD. Ahụhụ Cannabis Cannabinoids. 2018 Jun; 1: 65-72.
  26. Xu DH, Cullen BD, Tang M, Fang Y. Efdị Mma nke Mmanụ Ala Cannabidiol nke Na-ahụ Maka Mgbaàmà Symptomatic nke Neuropathy Peripheral nke Lower Extremities. Rlọ ọgwụ Bio. 2019 Dec 1. Elele anya.
  27. de Faria SM, nke Morais Fabrício D, Tumas V, et al. Mmetụta nke nnukwu ochichi cannabidiol na nchekasị na ịma jijiji nke a nwalere site na Nnwale Ekwu Okwu Ọha na Ọha na ndị nwere ọrịa Parkinson. J Psychopharmacol. 2020 Jenụwarị 7: 269881119895536. Lelee anya.
  28. Nitecka-Buchta A, Nowak-Wachol A, Wachol K, et al. Mmetụta Myorelaxant nke Transdermal Cannabidiol Ngwa na Ndị Ọrịa na TMD: Achọpụta Nke A, Nke Ugboro Abụọ. J Ahụike Med. 2019 Nov 6; 8. pii: E1886. Lelee anya.
  29. Masataka N. Anxiolytic Mmetụta nke Ntughari Cannabidiol ugboro ugboro na ndị nọ n'afọ iri na ụma na-enwe Nsogbu Nchegbu nke Ọha. N'ihu Psychol. Nwere ike ikwu. Lelee anya.
  30. Appiah-Kusi E, Petros N, Wilson R, et al. Mmetụta nke ọgwụgwọ cannabidiol dị mkpụmkpụ na nzaghachi na nrụgide mmekọrịta ọha na eze na isiokwu ndị nwere nnukwu ihe ize ndụ nke ịmalite psychosis. Psychopharmacology (Berl) Ọrịa. 2020 Jan 8. Lelee adịghị adị.
  31. Hussain SA, Dlugos DJ, Cilio MR, Parikh N, Oh A, Sankar R. Sịntetik na-emepụta ọgwụ ọgwụ cannabidiol maka ọgwụgwọ nke adịghị ike spasms: A otutu ụzọ-ọmụmụ 2. Akwụkwụ na-adọ Behav. 2020 Jan; 102: 106826. Lelee anya.
  32. Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Mmetụta na Ndidi nke Cannabidiol Sịntetik maka Ọgwụ nke Epilepsy Ọgwụ Na-eguzogide ọgwụ. N'ihu Neurol. 2019 Dec 10; 10: 1313. Lelee anya.
  33. "GW Pharmaceuticals plc na U.S. Subsidiary Greenwich Biosciences, Inc. Na-ekwuwapụta na E Derela EPIDIOLEX® (cannabidiol) Oral Solution Ọ Dịkwaghị Akpụrụ Na-achịkwa." GW Pharmaceuticals, 6 Eprel 2020. http://ir.gwpharm.com/node/11356/pdf. Mbipụta ndị nchụ nta akụkọ.
  34. Wiemer-Kruel A, Stiller B, Bast T. Cannabidiol na-arụkọ ọrụ nke ọma na Everolimus-Report nke Onye Ndidi nwere Tuberous Sclerosis Complex. Neuropediatrics. 2019. Elele anya.
  35. Mmelite nke ndị ahịa FDA: Ihe I Kwesịrị Knowmara Banyere Iji Cannabis, Gụnyere CBD, Mgbe Ọ Dị Ime ma ọ bụ Na-enye ara ara. U. Nchịkwa nri na ọgwụ ọjọọ (FDA). Ọktọba 2019. A na-enweta ya na: https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding.
  36. Taylor L, Crockett J, Tayo B, Morrison G. A Phase 1, Open-Label, Parallel-Group, Otu-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) na Ndị Isi Nke Dị Nwayọọ Na-arịa Ọrịa Hepatic. J Ahụike Pharmacol. Ọrịa. 2019; 59: 1110-1119. Lelee anya.
  37. Szaflarski JP, Hernando K, Bebin EM, et al. A na-ejikọta ọkwa ọkwa plasma dị elu nke Cannabidiol dị elu na nzaghachị ka mma mgbe a gwọchara ya na cannabidiol. Akwụkwụ na-adọ Behav. Ọrịa. 2019; 95: 131-136. Lelee anya.
  38. Pretzsch CM, Voinescu B, Mendez MA, et al. Ọgwụgwọ Mmetụta nke cannabidiol (CBD) na arụ ọrụ dị ala na arụmọrụ na-arụ ọrụ na ụbụrụ nke ndị toro eto na-enweghị ma na-enweghị ọrịa autism (ASD). J Psychopharmacol. 2019: 269881119858306. Lelee anya.
  39. Pretzsch CM, Freyberg J, Voinescu B, et al. Ọgwụgwọ Mmetụta nke cannabidiol na ụbụrụ obi ụtọ na usoro mgbochi; a na-achịkwa otu ebe a na-achịkwa ebe a na-achịkwa ebe a na-eme ka ọ bụrụ ihe na-eme ka magnetic resonance spectroscopy na ndị okenye nwere ma na-enweghị ọgba aghara nke autism. Neuropsychopharmacology. 2019; 44: 1398-1405. Lelee anya.
  40. Onye Patrician A, Versic-Bratincevic M, Mijacika T, et al. Nyocha nke Dzọ Mbupu Ọhụrụ maka Oral Cannabidiol na Ahụ Ike: A Na-enwe Ọdịdị, Abụọ na-ekpuchi Anya, Ọmụmụ Pharmacokinetics Na-achịkwa. Adv Ther. 2019. Elele anya.
  41. Martin RC, Gaston TE, Thompson M, et al. Mgbakwunye Akpịrị na-arụ ọrụ na-eso ogologo oge cannabidiol jiri ndị okenye nwere epilepsy na-eguzogide ọgwụ. Akwụkwụ na-adọ Behav. Ọrịa. 2019; 97: 105-110. Lelee anya.
  42. Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Ihe akaebe nke mmekorita ogwu ogwu di omimi n'etiti cannabidiol na tacrolimus. Am J Transplant. 2019; 19: 2944-2948. Lelee anya.
  43. Laux LC, Bebin EM, Checketts D, et al. Ogologo oge na nrụpụta ọrụ nke cannabidiol na ụmụaka na ndị okenye nwere ọgwụgwọ Lennox-Gastaut syndrome ma ọ bụ ọrịa Dravet na-eguzogide ọgwụ: Nsonaazụ mmemme mmemme gbasaa. Akwụkwụ na-adọ Res. Ọrịa. 2019; 154: 13-20. Lelee anya.
  44. Knaub K, Sartorius T, Dharsono T, Wacker R, Wilhelm M, Schön C. Ngwurugwu Ntanye Ọgwụ Na-eme Onwe Onwe Ya (SEDDS) Dabere na VESIsorb Technologymepụta Teknụzụ Na-emeziwanye Oral Bioavailability nke Cannabidiol na Ndị Ahụ Ike. Molekul. 2019; 24. pii: E2967. Lelee anya.
  45. Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Mmetụta nke cannabidiol na ọkwa plasma brivaracetam. Akwụkwụ. 2019; 60: e74-e77. Lelee anya.
  46. Heussler H, Cohen J, Silove N, et al. Nkeji edemede Oge 1/2, nyocha nyocha nke nchekwa, ndidi, na nrụpụta nke transdermal cannabidiol (ZYN002) maka ọgwụgwọ ọrịa ụmụaka na-emebi emebi X. J Neurodev Nsogbu. 2019; 11: 16. Lelee anya.
  47. Njikọ DG, Cook H, Ortori C, Barrett D, Lund JN, O'Sullivan SE. Palmitoylethanolamide na Cannabidiol Na-egbochi Mbufụt-na-akpata Hyperpermeability nke Ọkpụkpụ Mmadụ na Vitro na Na Vivo-A Randomized, Ebe a na-achịkwa ebe, Nnwale Na-achịkwa okpukpu abụọ. Ọrịa Bowel Dis. 2019; 25: 1006-1018. Lelee anya.
  48. Birnbaum AK, Karanam A, Marino SE, et al. Mmetụta nri na pharmacokinetics nke cannabidiol ọgwụ capsules na ndị ọrịa toro eto na-ajụ ajụ. Akwụkwụ. 2019 Ọgọstị; 60: 1586-1592. Lelee anya.
  49. Arkell TR, Lintzeris N, Kevin RC, et al. Cannabidiol (CBD) ọdịnaya dị na mmanya na-ekpo ọkụ anaghị egbochi tetrahydrocannabinol (THC) - enweghị ntụpọ nke ịkwọ ụgbọala na cognition. Ọrịa Psychopharmacology (Berl). Ọrịa. 2019; 236: 2713-2724. Lelee anya.
  50. Anderson LL, Absalom NL, Abelev SV, et al. Coadminized cannabidiol na clobazam: Ihe omuma nke doro anya maka mmekorita nke pharmacodynamic na pharmacokinetic. Akwụkwụ. 2019. Elele anya.
  51. Ozi ngwaahịa maka Marinol. AbbVie. Ugwu Chicago, IL 60064. Ọgọst 2017.A na-enweta ya na: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
  52. Epidiolex (cannabidiol) na-edepụta ozi. Greenwich Biosciences, Inc., Carlsbad, CA, 2019. Odikwa na: https://www.epidiolex.com/sites/default/files/EPIDIOLEX_Full_Prescribing_Information.pdf (nweta 5/9/2019)
  53. Nkwupụta sitere n'aka FDA Commissioner Scot Gottlieb, MD, na mbinye aka nke Iwu Mmezi Ugbo na usoro ụlọ ọrụ nke ngwaahịa nke nwere mmanya na mkpụrụ osisi cannabis. Ebe nrụọrụ weebụ Nchịkwa nri na ọgwụ ọjọọ na U.S. A na-enweta ya na: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Nabata May 7, 2019).
  54. Iwu Mmelite Ugbo, S. 10113, 115th Cong. ma ọ bụ S. 12619, 115th Cong. .
  55. Nchịkwa Mgbochi Ogwu, Ngalaba Ikpe Ziri Ezi. Oge nke Ihe Achịkwa Achịkwa: Ntinye na Oge V nke Drugfọdụ FDA-Kwadoro Ọgwụ Na-ebu Cannabidiol; Ekwekọrita Change ka ikike chọrọ. Usoro ikpeazụ. Ndenye aha. 2018 Sep 28; 83: 48950-3. Lelee anya.
  56. Schoedel KA, Szeto I, Setnik B, et al. Nkọwa Mmetụta nwere ike nyochaa nke cannabidiol (CBD) na ndị ọrụ polydrug na-atụrụ ndụ: Usoro enweghị usoro, ihu abụọ, nke a na-achịkwa. Akwụkwụ na-adọ Behav. 2018 Nov; 88: 162-171. ma ọ bụ: 10.1016 / j.yebeh.2018.07.027. Epub 2018 Oct 2. Elele anya.
  57. Devinsky O, Verducci C, Thiele EA, et al. Ihe eji emeghe ederede nke CBD (Epidiolex®) dị ọcha na ndị ọrịa nwere nsogbu CDKL5 na Aicardi, Dup15q, na Doose syndromes. Akwụkwụ na-adọ Behav. 2018 Sep; 86: 131-137. Epub 2018 Jul 11. Lelee anya.
  58. Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, et al. Mmekọrịta Cannabidiol na-eme ka ugboro ugboro na ike nke ọdịdọ na-ebelata ma na-ebelata ihe ndị na-emerụ ahụ na mpempe akwụkwọ na-emeghe-na ọmụmụ ihe. Akwụkwụ na-adọ Behav. 2018 Ọkt; 87: 131-136. Epub 2018 Aug 9. Elele anya.
  59. Linares IM, Zuardi AW, Pereira LC, et al. Cannabidiol na-enye usoro ntụgharị uche nke U na-agbanwe agbanwe na nyocha ihu ọha. Braz J Isi mgbaka. 2019 Jenụwarị-Feb; 41: 9-14. Epub 2018 Oct 11. Lelee anya.
  60. Poklis JL, Mulder HA, Udo MR. Nchọpụta a na-atụghị anya ya nke cannabimimetic, 5F-ADB, na dextromethorphan na azụmahịa e nwere cannabidiol e-mmiri mmiri. Nnyocha Sci Int. 2019 Jenụwarị; 294: e25-e27. Epub 2018 Nov 1. Lelee anya.
  61. Hurd YL, Spriggs S, Alishayev J, et al. Na Na Na Na Na Na Na Na Na Na Na Na, Cannabidiol maka Mbelata nke agụụ na nchekasị nke ndị na-ahụ maka ọgwụ ọjọọ na ndị nwere Heroin Jiri Ọrịa: Ọnwụnwa Na-achịkwa Ebe A Na-ahụ Anya Abụọ. Am J Isi Ọrịa. 2019: appiajp201918101191. Lelee anya.
  62. Thiele EA, Marsh ED, French JA, et al. Cannabidiol na ndị ọrịa nwere njigide metụtara Lennox-Gastaut syndrome (GWPCARE4): usoro nke 3 na-achịkwa, nke nwere ìsì abụọ, nke na-achịkwa ebebo. Lancet. 2018 Mar 17; 391: 1085-1096. Lelee anya.
  63. Devinsky O, Patel AD, Obe JH, et al. Mmetụta nke Cannabidiol na nkwụsịtụ na ọrịa Lennox-Gastaut. N Engl J Ahụike. 2018 Mee 17; 378: 1888-1897. Lelee anya.
  64. Pavlovic R, Nenna G, Calvi L, et al. Mgbakwunye Àgwà dị mma nke "mmanụ Cannabidiol": Cannabinoids Ọdịnaya, Mkpịsị aka Terpene na Oxidation Stability nke European Comprecially Available Preparations. Molekul. 2018 Mee 20; 23. pii: E1230. Lelee anya.
  65. Jannasch F, Kröger J, Schulze MB. Ternkpụrụ nri na ụdị 2 ọrịa shuga: Akwukwo akwukwo nke oma na Meta-Analysis nke ihe omumu. N Nr. 2017 Jun; 147: 1174-1182. Lelee anya.
  66. Naftali T, Mechulam R, Marii A, et al. Obere obere cannabidiol dị mma ma ọ bụghị dị irè na ọgwụgwọ nke Ọrịa Crohn, usoro nchịkwa a na-achịkwa. Gwuo Dis Sci. 2017 Jun; 62: 1615-20. Lelee anya.
  67. Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol ọgwụgwọ maka njigide njigide na Sturge-Weber Syndrome. Pediatr Neurol. Ọrịa. 2017 Jun; 71: 18-23.e2. Lelee anya.
  68. Yeshurun ​​M, Shpilberg O, Herscovici C, et al. Cannabidiol maka mgbochi nke aka-vesos-usu-ọrịa mgbe allogeneic hematopoietic cell transplantation: nsonaazụ nke a adọ II ọmụmụ. Ọkpụkpụ ọbara Ọrịa Biol. Ọkt. 2015; 21: 1770-5. Lelee anya.
  69. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Mmekọrịta ọgwụ ọjọọ n'etiti clobazam na cannabidiol na ụmụaka nwere ọrịa akwụkwụ. Akwụkwụ. 2015 Ọgọstị; 56: 1246-51. Lelee anya.
  70. Devinsky O, Marsh E, Friedman D, et la. Cannabidiol na ndị ọrịa nwere epilepsy na-eguzogide ọgwụ: ikpe ikpe na-emeghe. Lancet Neurol. 2016 Mar; 15: 270-8. Lelee anya.
  71. 97021 Jadoon KA, Ratcliffe SH, Barrett DA, et al. Nrụpụta ọrụ na nchekwa nke cannabidiol na tetrahydrocannabivarin na glycemic na lipid parameters na ọrịa na ụdị 2-arịa ọrịa shuga: a randomized, abụọ-ìsì, placebo-achịkwa, yiri otu pilot pilot. Ọrịa shuga. Ọkt 2016; 39: 1777-86. Lelee anya.
  72. Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol dị ka ọgwụgwọ nwere ike ịrịa ọrịa na-efe efe na-efe efe (FIRES) na nnukwu nsogbu. J Nwa Neurol. 2017 Jenụwarị; 32: 35-40. Lelee anya.
  73. Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol dị ka ọgwụgwọ ọhụrụ maka epilepsy na-eguzogide ọgwụ na mgbagwoju tuberous sclerosis. Akwụkwụ. Lelee ihe omuma.
  74. Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; Mmemme UAB CBD. Mmekọrịta dị n'etiti cannabidiol na ọgwụ ndị a na-ejikarị eme ihe. Akwụkwụ. Ọrịa. 2017 Sep; 58: 1586-92. Lelee anya.
  75. Devinsky O, Obe JH, Laux L, et al. Ọnwụnwa nke cannabidiol maka njide na-eguzogide ọgwụ na Dravet Syndrome. N Engl J Ahụike. 2017 Mee 25; 376: 2011-2020. Lelee anya.
  76. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Nkọwa ziri ezi nke cannabidiol extracts rere n'ịntanetị. JAMA 2017 Nov; 318: 1708-9. Lelee anya.
  77. Malfait AM, Gallily R, Sumariwalla PF, et al. Achọpụta nke ọma Ndị na-abụghị ndị nwere ike ịmịnye mkpụrụ-mmanya cannabidiol bụ ọgwụgwọ na-egbochi ọrịa ogbu na nkwonkwo na ọrịa ogbu na nkwonkwo murine. Nyocha Natl Acad Sci USA 2000; 97: 9561-6. Lelee anya.
  78. Formukong EA, Evans AT, Evans FJ. Ọrụ ogwu na mgbochi mkpali nke ihe mejuputara nke Cannabis sativa L. Inflammation 1988; 12: 361-71. Lelee anya.
  79. Valvassori SS, Elias G, de Souza B, et al. Mmetụta nke cannabidiol na amphetamine na-emetụta nrụgide oxidative na-emetụta ụdị anụmanụ nke mania. Nyocha. J Psychopharmacol 2011; 25: 274-80. Lelee anya.
  80. Esposito G, Scuderi C, Savani C, et al. Ekele Cannabidiol na vivo blunts beta-amyloid na-ebute neuroinflammation site na igbochi okwu IL-1beta na iNOS. Br J Pharmacol 2007; 151: 1272-9. Lelee anya.
  81. Esposito G, De Filippis D, Maiuri MC, et al. Cannabidiol na-egbochi okwu nitric oxide synthase protein na mmepụta nitric oxide na beta-amyloid kpalitere PC12 neurons site na p38 MAP kinase na ntinye NF-kappaB. Neurosci Lett 2006; 399 (1-2): 91-5. Lelee anya.
  82. Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: ọgwụ ohuru na-ekwe nkwa maka nsogbu neurodegenerative? CNS Neurosci Ther 2009; 15: 65-75. Lelee anya.
  83. Bisogno T, Di Marzo Y. Ọrụ nke usoro endocannabinoid na ọrịa Alzheimer: eziokwu na nchepụta. Curr Pharm Des 2008; 14: 2299-3305. Lelee anya.
  84. Zuardi AW. Cannabidiol: site na cannabinoid na-adịghị arụ ọrụ na ọgwụ nwere ọtụtụ ọrụ. Mkpu Bras Psiquiatr 2008; 30: 271-80. Lelee anya.
  85. Izzo AA, Borelli F, Capasso R, et al. Ntughari Osisi na-abụghị psychotropic Cannabinoids: ohere ọgwụgwọ ọhụrụ site na ahịhịa ndụ oge ochie. Nddị Pharmacol Sci 2009; 30: 515-27. Lelee anya.
  86. Booz GW. Cannabidiol dị ka usoro ọgwụgwọ maka ọgwụgwọ maka ibelata mmetụta nke mbufụt na nrụgide oxidative. Ọrịa Na-ahụ Maka Ọrịa Ọrịa. 2011; 51: 1054-61. Lelee anya.
  87. Pickens JT. Ọrụ izu ike nke mmanya na mmekọrita ya na delta’-trans-tetrahydrocannabinol na ọdịnaya cannabidiol. Br J Pharmacol 1981; 72: 649-56. Lelee anya.
  88. Monti JM. Mmetụta mmetụta uche nke cannabidiol na oke. Psychopharmacology (Berl) 1977; 55: 263-5. Lelee anya.
  89. Karler R, Turkanis SA. Subacute Cannabinoid ọgwụgwọ: ọrụ na-eme ka ndị mmadụ ghara ịna-eme ihe na-adịghị mma na ụmụ oke. Br J Pharmacol 1980; 68: 479-84. Lelee anya.
  90. Karler R, Cely W, Turkanis SA. Ọrụ nke anticonvulsant nke cannabidiol na cannabinol. Ndụ Sci 1973; 13: 1527-31. Lelee anya.
  91. Kọntaktị PF, Wokin AL. Mmekọrịta Anticonvulsant nke cannabidiol na ethosuximide na oke. Pharmlọ ọgwụ Pharmacol 1977; 29: 500-1. Lelee anya.
  92. Consroe P, Wolkin A. Cannabidiol-antiepilpetic ọgwụ na-atụnyere na mmekọrịta na experimentally emee ka ihe ọdịdọ na oke. J Pharmacol gbasaa Ther 1977; 201: 26-32. Lelee anya.
  93. Carlini EA, Leite JR, Tannhauser M, Berardi AC. Leta: Cannabidiol na Cannabis sativa wepụ wepụ oke na oke megide ndị na-eme aghara. Lọ ọgwụ Pharmacol 1973; 25: 664-5. Lelee anya.
  94. Cryan JF, Markou A, Lucki I. Nyochaa ọrụ antidepressant na òké: mmepe na nso nso a na mkpa ọdịnihu. Nddị Pharmacol Sci 2002; 23: 238-45. Lelee anya.
  95. El-Alfy AT, Ivey K, Robinson K, et al. Ọgwụgwọ Idedị mmetụta antidepressant nke delta9-tetrahydrocannabinol na ndị ọzọ cannabinoids dịpụrụ adịpụ na Cannabis sativa L. Pharmacol Biochem Behav 2010; 95: 434-42. Lelee anya.
  96. Resstel LB, Tavares RF, Lisboa SF, et al. Ndị natara 5-HT1A na-etinye aka na ntinye aka nke omume cannabidiol nke mmeghachi omume nke omume na nke obi na nnukwu nrụgide na oke. Br J Pharmacol 2009; 156: 181-8. Lelee anya.
  97. Granjeiro EM, Gomes FV, ​​Guimaraes FS, et al. Mmetụta nke nchịkwa intracisternal nke cannabidiol na nzaghachi obi na omume na nnukwu nrụgide njide. Nyocha Pharmacol Biochem Behav 2011; 99: 743-8. Lelee anya.
  98. Murillo-Rodriguez E, Millan-Aldaco D, Palomero-Rivero M, et al. Ọgwụgwọ Cannabidiol, ihe mejuputara Cannabis sativa, na-edozi ura na oke. FEBS Akwụkwọ 2006; 580: 4337-45. Lelee anya.
  99. De Filippis D, Esposito G, Cirillo C, et al. Cannabidiol na-ebelata nsị nsị site na nchịkwa nke axis neuroimmune. Ejiri otu 2011; 6: e28159. Lelee anya.
  100. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Mgbanwe nke mediotemporal na ọrụ ventrostriatal na ụmụ mmadụ site na Delta9-tetrahydrocannabinol: ihe ndabere maka mmetụta nke Cannabis sativa na mmụta na psychosis. Ọrịa Gen 2009, 66: 442-51. Lelee anya.
  101. Dalton WS, Martz R, Lemberger L, et al. Mgbakwunye Mmetụta nke cannabidiol na mmetụta Delta-9-tetrahydrocannabinol. Nlekọta Ọgwụ Pharmacol Ther 1976; 19: 300-9. Lelee anya.
  102. Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol na-abawanye okwu Fos na ngwongwo ahụ ma ọ bụghị na dorsal striatum. Ndụ Sci 2004; 75: 633-8. Lelee anya.
  103. Moreira FA, Guimaraes FS. Cannabidiol na-egbochi hyperlocomotion nke ọgwụ psychomimetic na ụmụ oke na-ebute. Eur J Pharmacol 2005; 512 (2-3): 199-205. Lelee anya.
  104. Ogologo LE, Chesworth R, Huang XF, et al. Ntụle omume nke nnukwu na-adịghị ala ala Delta9-tetrahydrocannabinol na cannabidiol na ụmụ oke C57BL / 6JArc. Int J Neuropsychopharmacol nke 2010; 13: 861-76. Lelee anya.
  105. Zuardi AW, Rodriguez JA, Cunha JM. Mmetụta nke cannabidiol na ụdị anụmanụ na-ebu amụma banyere ọrụ antipsychotic. Ọrịa Psychopharmacology (Berl) 1991; 104: 260-4. Lelee anya.
  106. Malone DT, Jongejan D, Taylor DA. Cannabidiol na-agbanwe mbelata mmekọrịta mmadụ na ibe ya nke Delta-tetrahydrocannabinol dị ala na oke. Pharmacol Biochem Behav 2009; 93: 91-6. Lelee anya.
  107. Schubart CD, Sommer IE, Fusar-Poli P, et al. Cannabidiol dị ka ọgwụgwọ nwere ike ịgwọ ọrịa uche. Eur Neuropsychopharmacol 2014; 24: 51-64. Lelee anya.
  108. Campos AC, Moreira FA, Gomes FV, ​​et al. Mgbakwunye Usoro dị iche iche na-emetụta ikike ịba ọgaranya nke cannabidiol n'ọrịa psychiatric. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3364-78. Lelee anya.
  109. Fusar-Poli P, Allen P, Bhattacharyya S, et al. Na-agagharị Mgbanwe nke njikọta dị irè n'oge nhazi mmetụta uche site Delta 9-tetrahydrocannabinol na cannabidiol. Int J Neuropsychopharmacol nke 2010; 13: 421-32. Lelee anya.
  110. Casarotto PC, Gomes FV, ​​Resstel LB, Guimaraes FS. Cannabidiol na-emechi ihe na-eme ka olili-ili ozu: itinye aka nke ndị natara CB1. Behav Pharmacol 2010; 21: 353-8. Lelee anya.
  111. Uribe-Marino A, Francisco A, Castiblanco-Urbina MA, et al. Mmetụta na-egbochi mmetụta nke cannabidiol na omume ebumpụta ụwa na-atụ egwu nke ihe atụ nke ụjọ ọgụ na-adabere na anụ oriri na agwọ anụ ọhịa Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology 2012; 37: 412-21. Lelee anya.
  112. Campos AC, Guimaraes FS. Ntinye nke 5HT1A ndị nabatara na-agbasa mmetụta nhụjuanya nke cannabidiol na ụdị PTSD. Behav Pharmacol 2009; 20: S54.
  113. Resstel LB, Joca SR, Moreira FA, et al. Ọzọ Mmetụta nke cannabidiol na diazepam na omume omume na nke obi na-emetụta site na ọnọdụ ọnọdụ ọnọdụ na oke. Behav Brain Res 2006; 172: 294-8. Lelee anya.
  114. Moreira FA, Aguiar DC, Guimaraes FS. Mmetụta dị ka nchegbu nke cannabidiol na ule Vogel esemokwu ule. Prog Neuropsychopharmacol Biol Ọrịa 2006; 30: 1466-71. Lelee anya.
  115. Onaivi ES, Green MR, Martin BR. Nkọwa ọgwụ nke cannabinoids na elu na maze. J Pharmacol gbasaa Ther. 1990; 253: 1002-9. Lelee anya.
  116. Guimaraes FS, Chairetti TM, Graeff FG, Zuardi AW. Nchegbu nchegbu nke cannabidiol na elu-maze. Psychopharmacology (Berl) 1990; 100: 558-9. Lelee anya.
  117. Magen I, Avraham Y, Ackerman Z, et al. Cannabidiol na-eme ka mmetuta na mmerụ ahụ na-adịghị mma na ụmụ oke nwere ọnụọgụ bile. Nyocha. J Hepatol 2009; 51: 528-34. Lelee anya.
  118. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol na-eme ka nkwarụ obi, nrụgide oxidative, fibrosis, na ụzọ mgba ọkụ na mkpụrụ ndụ ọnwụ na-arịa ọrịa obi cardiomyopathy. Nyocha. 2010: 56: 2115-25. Lelee anya.
  119. El-Remessy AB, Khalifa Y, Ola S, et al. Cannabidiol na-echekwa akwara ozi azụ site na ịchekwa ọrụ glutamine synthetase na ọrịa shuga. Mol Vis 2010; 16: 1487-95. Lelee anya.
  120. El-Remessy AB, Al-Shabrawey M, Khalifa Y, et al. Neuroprotective na ọbara-retinal ihe mgbochi-ichebe mmetụta nke cannabidiol na-arịa ọrịa shuga. Am J Pathol 2006; 168: 235-44. Lelee anya.
  121. Rajesh M, Mukhopadhyay P, Batkai S, et al. Cannabidiol na-eme ka glucose dị elu na-ebute nzaghachi mkpali nke endothelial na nkwụsịtụ mgbochi. Am J Physiol Obi Circ Physiol 2007; 293: H610-H619. Lelee anya.
  122. Toth CC, Jedrzejewski NM, Ellis CL, Frey WH. Mgbanwe Cannabinoid nke mgbasa ozi nke nhụjuanya neuropathic na mkpokọta microglial na ụdị mgbu mgbu nke ọrịa 1 nke ọrịa mamịrị. Mol Mgbu 2010; 6:16. Lelee anya.
  123. Aviello G, Romano B, Borrelli F, et al. Mgbakwunye Chemopreventive mmetụta nke na-abụghị psychotropic phytocannabinoid cannabidiol na cancer colon cancer. Nyocha. J Mol Med (Berl) 2012; 90: 925-34. Lelee anya.
  124. Lee CY, Wey SP, Liao MH, et al. Ọgwụgwọ A comparasis ọmụmụ na cannabidiol na-emetụta apoptosis na murine thymocytes na EL-4 thymoma sel. Int Immunopharmacol 2008; 8: 732-40. Lelee anya.
  125. Massi P, Valenti M, Vaccani A, et al. 5-Lipoxygenase na anandamide hydrolase (FAAH) na-agbagha ọrụ antitumor nke cannabidiol, cannabinoid na-abụghị psychoactive. Nyocha. J Neurochem 2008; 104: 1091-100. Lelee anya.
  126. Valenti M, Massi P, Bolognini D, et al. Cannabidiol, ihe na-abụghị psychoactive cannabinoid onyinye na-egbochi mwepụ nke glioma cell na mwakpo. 34th National Congress nke Italian Society of Pharmacology 2009.
  127. Torres S, Lorente M, Rodriguez-Fornes F, et al. Ọgwụgwọ Nchịkọta nkwekọrịta zuru oke nke cannabinoids na temozolomide megide glioma. Ọrịa Cancer Ther 2011; 10: 90-103. Lelee anya.
  128. Jacobsson SO, Rongard E, Stridh M, et al. Mgbakwunye Mmetụta na-adabere na tamoxifen na cannabinoids na C6 glioma cell viability. Biochem Pharmacol 2000; 60: 1807-13. Lelee anya.
  129. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol na-ebute ọnwụ cell na mkpụrụ ndụ ara ure site na ịhazi okwu obe n'etiti apoptosis na autophagy. Ọrịa Cancer Ther 2011; 10: 1161-72. Lelee anya.
  130. McAllister SD, Murase R, Christian RT, et al. Pzọ na-agbatị mmetụta nke cannabidiol na Mbelata nke ọrịa ara ure cell, mbuso agha, na metastasis. Ọrịa ara ara na-agwọ 2011; 129: 37-47. Lelee anya.
  131. McAllister SD, Christian RT, Horowitz MP, et al. Ọgwụgwọ Cannabidiol dị ka onye na-emechi akwụkwọ akụkọ Id-1 nke na-egosi mkpụrụ ndụ ara ara ara ike. Ọrịa Cancer Ther 2007; 6: 2921-7. Lelee anya.
  132. Ligresti A, Moriello AS, Starowicz K, et al. Ọgwụgwọ Ọrụ antitumor nke osisi cannabinoids na-ekwusi ike na mmetụta nke cannabidiol na carcinoma ara mmadụ. J Pharmacol Na-akọwa 2006; 318: 1375-87. Lelee anya.
  133. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol dị ka ọgwụ nwere ọgwụ mgbochi. Br J Clin Pharmacol 2013; 75: 303-12. Lelee anya.
  134. Schubart CD, Sommer IE, van Gastel WA, et al. A na-ejikọta Cannabis nwere ọdịnaya dị ukwuu nke cannabidiol na ahụmịhe dị ole na ole. Schizophr Mkpebi 2011; 130 (1-3): 216-21. Lelee anya.
  135. Englund A, Morrison PD, Nottage J, et al. Cannabidiol na-egbochi THC-kpalitere mgbaàmà paranoid na ncheta hippocampal na-adabere na ncheta. Nyocha. J Psychopharmacol 2013; 27: 19-27. Lelee anya.
  136. Devinsky O, Cilio MR, Cross H, et al. Achọpụtara Cannabidiol: nkà mmụta ọgwụ na ọrụ ọgwụgwọ nwere ike na epilepsy na ọrịa ndị ọzọ na-adịghị agwọ ọrịa. Akwụkwụ na-adọ 2014; 55: 791-802. Lelee anya.
  137. Serpell MG, Notcutt W, Collin C. Sativex iji ogologo oge: nyocha a na-emeghe na ndị ọrịa nwere spasticity n'ihi ọtụtụ sclerosis. Nyocha. J Neurol 2013; 260: 285-95. Lelee anya.
  138. Notcutt W, Langford R, Davies P, et al. Achọpụta Otu a na-achịkwa ebebo, otu ihe ọmụmụ, nke a na-ahụkarị nke ọmụmụ banyere isiokwu nwere mgbaàmà nke spasticity n'ihi ọtụtụ sclerosis ndị na-anata Sativex ogologo oge (nabiximols). Igwe ihe omimi 2012; 18: 219-28. Lelee anya.
  139. Brady cm, DasGupta R, Dalton C, et al. A na-emeghe aha ọmụmụ nke extracts dabeere extracts maka eriri afo dysfuntion na elu multiple sclerosis. Igwe ihe omimi 2004; 10: 425-33. Lelee anya.
  140. Kavia RB, De Ridder D, Constantinescu CS, et al. Ọnwụnwa a na-achịkwa nke Sativex ka ọ na-emeso overactivity na otutu sclerosis. Igwe ihe omimi 2010; 16: 1349-59. Lelee anya.
  141. Wade DT, Makela PM, Hlọ H, et al. Ogologo oge iji ọgwụgwọ ị cannabisụ mmanya na-adị na spasticity na mgbaàmà ndị ọzọ na otutu sclerosis. Igwe ihe omimi 2006; 12: 639-45. Lelee anya.
  142. Novotna A, Mares J, Ratcliffe S, et ọc A randomized, abụọ-ìsì, placebo-achịkwa, yiri-otu, enriched-imewe ọmụmụ nke nabiximols * (Sativex), dị ka tinye-on ọgwụ, na isiokwu na refractory spasticity kpatara multiple sclerosis. Eur J Neurol 2011; 18: 1122-31. Lelee anya.
  143. Isi. GW na weebụsaịtị.Odikwa na: http://www.gwpharm.com/about-us-overview.aspx. Nweta: May 31, 2015.
  144. Cannabidiol Na-egosi Na Nchịkọta nri. Eke Ọgwụ weebụsaịtị. https://naturalmedicines.therapeuticresearch.com/news/news-items/2015/march/cannabidiol-now-showing-up-in-dietary-supplement.aspx. (Nabata May 31, 2015).
  145. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Mmetụta nke ipsapirone na cannabidiol na nchegbu ọmịiko mmadụ. J Psychopharmacol 1993; 7 (1 Suppl): 82-8. Lelee anya.
  146. Iguzogide EG, Fentiman AF Jr, Foltz RL. Ndị metabolites a na-ejide ogologo oge nke delta9- na delta8-tetrahydrocannabinols ndị a maara dị ka ndị na-ejikọta mmanụ fatty acid. Res Commun Chem Pathol Pharmacol 1976; 14: 13-28. Lelee anya.
  147. Samara E, Bialer M, Mechoulam R. Pharmacokinetics nke cannabidiol na nkịta. Mwepụ ọgwụ mgbochi ọgwụ 1988; 16: 469-72. Lelee anya.
  148. Kọntaktị P, Sandyk R, Snider SR. Meghee aha nyocha nke cannabidiol na nsogbu mmegharị dystonic. Int J Neurosci 1986; 30: 277-82. Lelee anya.
  149. Crippa JA, Derenusson GN, Ferrari TB, et al. Ihe ndabere nke nchegbu nke cannabidiol (CBD) na ọgba aghara nchegbu ọha na eze: akụkọ mbido. Nyocha. J Psychopharmacol 2011; 25: 121-30. Lelee anya.
  150. Bornheim LM, Everhart ET, Li J, Correia MA. Njirimara nke cannabidiol nke mgbasa ozi cytochrome P450 adịghị arụ ọrụ. Biochem Pharmacol 1993; 45: 1323-31. Lelee anya.
  151. Harvey DJ. Ntinye, nkesa, na biotransformation nke cannabinoids. Marijuana na ogwu. 1999; 91-103.
  152. Yamaori S, Ebisawa J, Okushima Y, et al. Mgbochi nke mmadụ P450 3A cytochrome isoforms site na cannabidiol: ọrụ nke phenolic hydroxyl iche iche na resorcinol moiety. Ndụ Sci 2011; 88 (15-16): 730-6. Lelee anya.
  153. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, bụ isi phytocannabinoid, dịka onye na-eme ihe na-adịghị ike nke CYP2D6. Ngwunye Ọgwụ Ọgwụ 2011; 39: 2049-56. Lelee anya.
  154. Yamaori S, Maeda C, Yamamoto I, Watanabe K. Ngbochi dị iche iche nke mmadụ cytochrome P450 2A6 na 2B6 site na isi phytocannabinoids. Ọrịa na-egbu egbu 2011; 29: 117-24.
  155. Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Njirimara nke isi phytocannabinoids, cannabidiol na cannabinol, dị ka ndị na-eme ihe nchịkwa nwere ike igbochi mmadụ enzyme CYP1. Biochem Pharmacol 2010; 79: 1691-8. Lelee anya.
  156. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol maka ọgwụgwọ nke psychosis na ọrịa Parkinson. J Psychopharmacol 2009; 23: 979-83. Lelee anya.
  157. Morgan CJ, Das RK, Joye A, et al. Cannabidiol na-ebelata ikikere siga na ndị na-ese ụtaba: nchọpụta mbido. Ahụhụ Behav 2013; 38: 2433-6. Lelee anya.
  158. Pertwee RG. Diversedị ọgwụ dịgasị iche iche nke CB1 na CB2 nke ọgwụ atọ nke cannabinoids: delta9-tetrahydrocannabinol, cannabidiol na delat9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215. Lelee anya.
  159. Leweke FM, Kranaster L, Pahlisch F, et al. Mgbakwunye Mmetụta nke cannabidiol na ọgwụgwọ schizophrenia - usoro ntụgharị. Schizophr Bull 2011; 37 (Nyefee 1): 313.
  160. Leweke FM, Piomelli D, Pahlisch F, et al. Mgbakwunye Cannabidiol na-eme ka anandamide na-egosi ma na-ebelata mgbaàmà nke uche nke schizophrenia. Ọrịa Ọrịa 2012; 2: e94. Lelee anya.
  161. Carroll CB, Bain PG, Na-akwa L, et al. Cannabis maka dyskinesia na ọrịa Parkinson: ọmụmụ ihe abụọ na-ekpuchi ìsì. Neurology 2004; 63: 1245-50. Lelee anya.
  162. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol na-ebelata nchekasị nke okwu ihu ọha na-eme ka a gwọọ ya na ndị ọrịa-na-adịghị mma. Neuropsychopharmacology 2011; 36: 1219-26. Lelee anya.
  163. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, nke Cannabis sativa mejuputara ya, dika ogwu antipsychotic. Braz J Med Biol Nkwụ 2006; 39: 421-9. Lelee anya.
  164. Yadav V, Bever C Jr, Bowen J, et al. Nke a Nchịkọta nke usoro ihe akaebe na-egosi: nkwado na ọgwụ ọzọ na ọtụtụ sclerosis: akụkọ banyere kọmitii mmepe mmepe nke American Academy of Neurology. Ọrịa. 2014; 82: 1083-92. Lelee anya.
  165. Na-atụ ụjọ B, Sherman M. Ọmụmụ ihe ọmụmụ abụọ na-adịghị mma nke cannabidiol dị ka onye na-emegide onwe ya. Marijuana '90 International Conference on Cannabis and Cannabinoids 1990; 2: 5.
  166. Srivastava, M. D., Srivastava, B. I., na Brouhard, B. Delta9 tetrahydrocannabinol na cannabidiol gbanwere mmepụta cytokine site na mkpụrụ ndụ na-adịghị ahụ mmadụ. Immunopharmacology 1998; 40: 179-185. Lelee anya.
  167. Cunha, JM, Carlini, EA, Pereira, AE, Ramos, OL, Pimentel, C., Gagliardi, R., Sanvito, WL, Lander, N., na Mechoulam, R. Ọchịchị na-adịghị ala nke cannabidiol nye ndị ọrụ afọ ofufo ahụike na ndị ọrịa akwụkwụ . Nkà ọgwụ na ọgwụ 1980; 21: 175-185. Lelee anya.
  168. Carlini EA, Cunha JM. Hypnotic na mmetụta antiepileptic nke cannabidiol. J Clin Pharmacol 1981; 21 (8-9 Ntinye): 417S-27S. Lelee anya.
  169. Zuardi, A. W., Shirakawa, I., Finkelfarb, E., na Karniol, I. G. Omume nke cannabidiol na nchekasị na mmetụta ndị ọzọ nke Delta 9-THC mepụtara na isiokwu ndị nkịtị. Psychopharmacology (Berl) 1982; 76: 245-250. Lelee anya.
  170. Ames, F. R. na Cridland, S. Anticonvulsant utịp nke cannabidiol. Nneka Ndubuisi 1-4-1986; 69: 14. Lelee anya.
  171. Ohlsson, A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., na Hollister, L. E. Nanị mkpụrụ ọgwụ kinetik deuterium nke akpọrọ cannabidiol n'ime mmadụ mgbe ị smokingụ sịga na nchịkwa intravenous. Gburugburu Mass Spectrom. Ọrịa. 1986; 13: 77-83. Lelee anya.
  172. Wade, D. T., Collin, C., Stott, C., na Duncombe, P. Meta-nyochara nrụpụta ọrụ na nchekwa nke Sativex (nabiximols), na spasticity na ndị nwere ọtụtụ sclerosis. Otutu. Ọrịa. 2010; 16: 707-714. Lelee anya.
  173. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, M ., Zapletalova, O., Pikova, J., na Ambler, Z. A abụọ-ìsì, randomized, placebo-achịkwa, ukem-otu ọmụmụ nke Sativex, na isiokwu na mgbaàmà nke spasticity n'ihi otutu sclerosis. Neurol.Res. Ọrịa. 2010; 32: 451-459. Lelee anya.
  174. Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., na Fusar-Poli, P. Cannabis na nchegbu: nyocha dị oke egwu nke ihe akaebe. Hum.Psychopharmacol. Ọrịa. 2009; 24: 515-523. Lelee anya.
  175. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., na Schram, K. Na-achịkwa ikpe ahụike nke cannabidiol na ọrịa Huntington. Aclọ ọgwụ Pharmacol. Behav. 1991; 40: 701-708. Lelee anya.
  176. Harvey, D. J., Samara, E., na Mechoulam, R. Ngwakọta metabolism nke cannabidiol na nkịta, oke na mmadụ. Aclọ ọgwụ Pharmacol. Behav. 1991; 40: 523-532. Lelee anya.
  177. Collin, C., Davies, P., Mutiboko, I. K., na Ratcliffe, S. Randomized achịkwa ikpe nke ọgwụ dabeere ọgwụ na spasticity kpatara otutu sclerosis. Eur, J. Neurol. Ọrịa. 2007; 14: 290-296. Lelee anya.
  178. Massi, P., Vaccani, A., Bianchessi, S., Costa, B., Macchi, P., na Parolaro, D. Ndị na-abụghị psychoactive cannabidiol na-akpata ịmalite ịmalite ọrụ na nrụgide oxidative na mkpụrụ ndụ glioma mmadụ. Cell Mol. Ndụ Sci. 2006; 63: 2057-2066. Lelee anya.
  179. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., na Gallily, R. Cannabidiol na-ebelata ọrịa shuga na ụmụ oke na-arịa ọrịa shuga na-abụghị oke ibu. Nchekwa onwe 2006; 39: 143-151. Lelee anya.
  180. Watzl, B., Scuderi, P., na Watson, R. R. Marijuana ihe ndị na-eme ka ihe mgbochi mkpụrụ ndụ mononuclear sel nke mkpụrụ ndụ interferon-gamma na-ebelata interleukin-1 alpha in vitro. Int J Immunopharmacol. 1991; 13: 1091-1097. Lelee anya.
  181. Consroe, P., Kennedy, K., na Schram, K. Nnwale nke plasma cannabidiol site na capillary gas chromatography / ion trap mass spectroscopy na-esote ọgwụ dị elu na-emeghachi kwa ụbọchị nchịkwa mmadụ na ụmụ mmadụ. Aclọ ọgwụ Pharmacol. Behav. 1991; 40: 517-522. Lelee anya.
  182. Barnes, M. P. Sativex: nrụpụta ọrụ na ndidi na ọgwụgwọ nke mgbaàmà nke otutu sclerosis na mgbu neuropathic. Ọkachamara.Opin.Pharmacother. 2006; 7: 607-615. Lelee anya.
  183. Wade, D. T., Makela, P., Robson, P., House, H., na Bateman, C. Ndi ogwu ogwu ndi ogwu nwere ihe zuru oke ma obu ihe puru iche na ihe mgbaàmà na otutu sclerosis? A na-ahụ ụzọ abụọ na-ahụ ụzọ, na-enweghị usoro, na-achịkwa ebebo maka ndị ọrịa 160. Otutu. Ọrịa. 2004; 10: 434-441. Lelee anya.
  184. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., na Izzo, AA Neuroprotective mmetụta nke cannabidiol, ihe na-abụghị nke psychoactive sitere na Cannabis sativa, na beta-amyloid-induced nsị na mkpụrụ ndụ PC12. N Neurochem. 2004; 89: 134-141. Lelee anya.
  185. Massi, P., Vaccani, A., Ceruti, S., Colombo, A., Abbracchio, M. P., na Parolaro, D. Mmetụta nke antitumor nke cannabidiol, cannabinoid na-enweghị uche, na usoro glioma cell. J Pharmacol gbasapụ. Ọrịa. 2004; 308: 838-845. Lelee anya.
  186. Crippa, JA, Zuardi, AW, Garrido, GE, Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, PM, Hallak, JE, McGuire, PK, na Filho, Busatto G. Mmetụta nke cannabidiol (CBD) na mpaghara ọbara ụbụrụ. Neuropsychopharmacology 2004; 29: 417-426. Lelee anya.
  187. Wade, D. T., Robson, P., House, H., Makela, P., na Aram, J. Nnyocha a na-achịkwa nke ọma iji chọpụta ma mkpụrụ osisi ahịhịa niile nwere ike melite mgbaàmà ndị na-adịghị mma. Nleghachi. Rehabil. Ọrịa. 2003; 17: 21-29. Lelee anya.
  188. Covington TR, et al. Akwụkwọ ntuziaka nke ọgwụ na-abụghị ọgwụ. Nke 11. Washington, DC: American Pharmaceutical Association, 1996.
Nyochaa ikpeazụ - 12/18/2020

Oge Kachasị ỌHụRụ

Ntụziaka Italian nke Rocco DiSpirito Slimmed-down
Ndu

Ntụziaka Italian nke Rocco DiSpirito Slimmed-down

Onye i i nri na onye na-ere ahịa kacha mma Rocco Di pirito ọ gara n'Itali dum iji mụta ihe nzuzo nke nri ite n'aka ndị na-e i ya nke ọma-Ndị nne Ịtali-maka akwụkwọ nri ọhụrụ ya, Ugbu a, rie ih...
Ị ga -achọ n'ezie ịgụ n'ime mmemme egwu Peloton 'Ihe niile maka Otu' n'izu ụka a
Ndu

Ị ga -achọ n'ezie ịgụ n'ime mmemme egwu Peloton 'Ihe niile maka Otu' n'izu ụka a

Mgbe enweghị mkparịta ụka IRL nke afọ gara aga, ị nwere ike na-eti mkpu iji mejupụta kalenda gị ọtụtụ mmemme na-apụtaghị n'ụlọ dịka mmadụ kwere omume. Ọ dị mma, ọ dị nwute imebi atụmatụ ọ bụla dị ...